Nefazodone, sold formerly under the brand names Serzone, Dutonin, and Nefadar among others, is an atypical antidepressant medication which is used in the treatment of depression and for other uses.

[9] Side effects of nefazodone include dry mouth, sleepiness, nausea, dizziness, blurred vision, weakness, lightheadedness, confusion, and postural low blood pressure, among others.

[18] Common and mild side effects of nefazodone reported in clinical trials more often than placebo include dry mouth (25%), sleepiness (25%), nausea (22%), dizziness (17%), blurred vision (16%), weakness (11%), lightheadedness (10%), confusion (7%), and orthostatic hypotension (5%).

[32] Nefazodone has low but significant affinity for the serotonin, norepinephrine, and dopamine transporters as well, and therefore acts as a weak serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).

[30] It has low but potentially significant affinity for the histamine H1 receptor, where it is an antagonist, and hence may have some antihistamine activity.

[3] The drug has at least four active metabolites, which include hydroxynefazodone, para-hydroxynefazodone, triazoledione, and meta-chlorophenylpiperazine (mCPP).

[2] As such, in spite of its relatively low plasma concentrations, brain exposure to mCPP may be substantial, whereas that of hydroxynefazodone may be minimal.

[37] Nefazodone was discovered by scientists at Bristol-Myers Squibb (BMS) who were seeking to improve on trazodone by reducing its sedating qualities.

[37] BMS obtained marketing approvals for nefazodone worldwide, including in the United States and Europe, in 1994.

[43][44] The FDA issued a response to the petition in June 2004 and filed a motion to dismiss, and Public Citizen withdrew the suit.

[7] Generic versions were introduced in the United States in 2003[12] and Health Canada withdrew the marketing authorization that same year.

[12][13][45] By that time, BMS had already withdrawn the drug from the market in Europe, Australia, New Zealand, and Canada.

[4][5][48][6] Nefazodone has been marketed under a number of brand names including Dutonin (ATTooltip Austria, ESTooltip Spain, IETooltip Ireland, UKTooltip United Kingdom), Menfazona (ESTooltip Spain), Nefadar (CHTooltip Switzerland, DETooltip Germany, NOTooltip Norway, SETooltip Sweden), Nefazodone BMS (ATTooltip Austria), Nefazodone Hydrochloride Teva (USTooltip United States), Reseril (ITTooltip Italy), Rulivan (ESTooltip Spain), and Serzone (AUTooltip Australia, CATooltip Canada, USTooltip United States).